Spinifex Raises $45 Million In Series C For Novel Neuropathic Pain Product
This article was originally published in The Pink Sheet Daily
Executive Summary
The Australian biotech attracts new investors from the U.S. and Europe to fund Phase IIb clinical trials of its lead product for post-herpetic neuralgia and to expand its U.S. operations.